BNT111 generated antigen‐specific CD4+ and CD8+ T cellsMost patients showed PRBNT111‐induced T cells effectively targeted melanoma cells with strong cytotoxicityT‐cell responses persisted for more than 1 yearTwo melanoma patients achieved >35% tumour regression with BNT111 in combination with anti‐PD1 therapy. Here, PDCD1 is linked to neoplasm.